Immune monitoring of pediatric heart transplant recipients through serial donor specific antibody testing - An initial experience and review of the literature

Progress in Pediatric Cardiology

Volumn 32, Issue 1, 2011, Pages 43-49

  Gambetta, K ^a   Tambur, A ^b   Pahl, E ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Allosensitization; Antibody mediated rejection; Cardiac allograft vasculopathy; Donor specific antibodies; Heart transplantation

Indexed keywords

ANTIBODY; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOSENSITIZATION; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOMYOPATHY; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; DONOR SELECTION; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HLA SYSTEM; HLA TYPING; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; PLASMAPHERESIS; PRIORITY JOURNAL; SENSITIZATION;

EID: 79961173631     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2011.06.009     Document Type: Article

References (44)

1. Kirk R., Edwards L., Aurora P., et al. Registry of the International Society for Heart and Lung Transplantation: twelfth official pediatric HTx report - 2009. J Heart Lung Transplant 2009, 28:993-1006.
2. Lindenfeld J., Miller G.G., Shaker S.F., et al. Drug therapy in the heart transplant recipient: part I: cardiac suppression and immunosuppression drugs. Circulation 2004, 110(24):3734-3740.
3. Baran D., Carboni M., Dangler T., et al. The International Society of Heart and Lung Transplantation ISHLT guidelines. Task force 2: immunosuppression and rejection Nov. 8, 2010.
4. Singh N., Pirsch J., Smaniego M. Antibody mediated rejection: treatment alternatives and outcomes. Transplant Rev. 2009, 23:34-46.
5. Kobashigawa J. Contemporary concepts in noncellular rejection. Heart Fail Clin. 2007, 3:11-15.
6. Kobashigawa J., Crespo-Leiro M., Ensminger S., et al. ISHLT consensus. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011, 30(3):252-269.
7. Michaels P., Espejo M., Kobashigawa, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. Journal of Heart and Lung Transplantation 2003, 22:58-69.
8. Billingham M.E. Histopathology of graft coronary artery disease. J Heart Lung Transplant 1990, 119(3):538-544.
9. Pahl E., Naftel D.C., Kuhn M., et al. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9year multi-institutional study. J Heart Lung Transplant 2005, 24:645-651.
10. Schmauss D., Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008, 117:2131-2141.
11. Kaczmarek I., Deutsch M., Kauke T., et al. Donor specific HLA alloantibodies: long term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008, 6(3):229-235.
12. Levinson W. Major histocompatibility complex and transplantation. Review of medical microbiology and immunology 2008, McGraw-Hill Publishing, New York. Tenth Edition. W. Levinson (Ed.).
13. Tiercy J.M. Molecular basis of HLA polymorphism: implication in clinical transplantation. Transpl Immunol 2002, 9:173.
14. Sheldon S., Hasleton P., Yonan N., et al. Rejection in heart transplantation strongly correlated with HLA-DR antigen mismatch. Transplantation 1994, 58(6):719-722.
15. Herzberg G., Rossi A., Courtney M., Gelb B. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients. J Heart Lung Transplant 1998, 17(12):1195-1200.
16. Vasilescu E., Ho E., De La Torre L., et al. Anti-HLA antibodies in heart transplantation. Transplant Immunol. 2004, 12:177-183.
17. Gajarski R., Pearce F. Recipient evaluation: medical and psychosocial morbidities. Pediatric Htx. 2007, volume 2:19-32. Elsevier, Philadelphia. C. Canter, J. Kirklin (Eds.).
18. Shaddy R.E., Fuller T.C. The sensitized pediatric heart transplant candidate: causes, consequences, and treatment options. Pediatr Transplant 2005, 9:208-214.
19. Scornik J.C., Pfaff W.W., Howard R.J., et al. Increased antibody responsiveness to blood transfusions in pediatric patients. Transplantation 1994, 58:1361-1365.
20. Kobashigawa J.A., Sabad A., Drinkwater D., et al. Pretransplant panel reactive antibody screens: are they truly a marker of poor outcome after cardiac transplantation?. Circulation 1996, 94(suppl II):II294-II297.
21. Tambur A.R., Bray R.A., Takemoto S.K., et al. Flow cytometric detection of HLA specific antibodies as a predictor of heart allograft antibody rejection. Transplantation 2000, 70:1055-1059.
22. Di Fillippo S., Girnita A., Webber S., et al. Impact of elisa-detected HLA antibodies on pediatric allograft outcome. Hum Immunol. 2005, 66:513-518.
23. Holt D.B., Lublin D.M., Phelan D.L., et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing perioperative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007, 26:1163-1169.
24. Pollock-BarZiv S., den Hollander N., Ngan B., et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving management and assessment of intermediate outcomes in a high-risk population. Circulation 2007, 116(11 Supplement):I172-I178.
25. Velez M., Johnson M. Management of allosensitized cardiac transplant candidates. Transplant Rev. 2009, 23:235-247.
26. Jacobs J., Quintessenza J., Boucek R., et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg. 2004, 78:1703-1709.
27. Rossano J., Morales D., Zafar F., et al. Impact of antibodies against human leukocyte antigens on long term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing Database. J Thorac Cardiovasc Surg. 2010, 140:694-699.
28. Feingold B., Bowman P., Zeevi A., et al. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant 2007, 26:565-571.
29. Almond C., Thiagarajan R., Piercey G., et al. Waiting list mortality among children listed for heart transplantation in the United States. Circulation 2009, 119:717-727.
30. Pisani B.A., Mullen G.M., Malinowska K., et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999, 18:701-706.
31. Leech S., Lopez-Cepero M., LeFor W., et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant 2006, 20:476-484.
32. Jordan S., Tyan D., Stablein D., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly-HLA sensitized adult patients with end stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004, 15:3256-3262.
33. Dowling R., Jones J., Carroll M., Gray L. Use of intravenous immunoglobulin in sensitized LVAD recipients. Transplant Proc. 1998, 30:1110-1111.
34. John R., Lietz K., Burke E., et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999, 100:II229-II235.
35. Zangwill S., Ellis T., Stendahl G., Zahn A., Berger S., Tweddell J. Practical application of the virtual crossmatch. Pediatr Transplant 2007, 11(6):650-654.
36. Takemoto S., Zeevi A., Feng S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004, 4(7):1033-1041.
37. Ho E.K., Vlad G., Vasilescu E., et al. Pre and post transplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol. 2011, 72:5-10.
38. Kaczmarek I., Deutsch M., Kauke T., et al. Donor specific HLA alloantibodies: long term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008, 6(3):229-235.
39. Tambur A.R., Pamboukian S.V., Costanzo M.R., et al. The presence of HLA directed antibodies after Htx is associated with poor allograft outcomes. Transplantation 2005, 80:1019-1025.
40. Stastny P., Lavingia B., Fixler D., Yancy C., Ring W. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation 2007, 84(6):738-745.
41. Smith J., Banner N., Hamour I., et al. De Novo donor HLA specific antibodies after Htx are an independent predictor of poor patient survival. Am J Transplant 2011, 11:312-319.
42. Singh N., Pirsch J., Smaniego M. Antibody mediated rejection: treatment alternatives and outcomes. Transplant Rev 2009, 23:34-46.
43. Wu G., Kobishagawa J., Fishbein M., et al. Asymptomatic antibody mediated rejection after Htx predicts poor outcomes. J Heart Lung Transplant 2009, 28(5):417-422.
44. Kfoury A., Hammond M.E., Snow G., et al. Early screening for antibody mediated rejection in asymptomatic heart transplant recipients. J Heart Lung Transplant 2007 Dec, 26(12):1264-1269.